Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: The importance of involved-field radiotherapy

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1848-1853

  Sher, D J ^a   Mauch, P M ^a   Van Den Abbeele, A ^b   LaCasce, A S ^b   Czerminski, J ^a   Ng, A K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Hodgkin's lymphoma; Involved field radiotherapy; PET; Radiotherapy; Response adapted therapy

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; GEMCITABINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 71049116335     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp071     Document Type: Article

References (17)

1. Hoppe RT. Hodgkin's lymphoma: The role of radiation in the modern combined strategies of treatment. Hematol Oncol Clin North Am 2007; 21: 915-927.
2. Spaepen K, Stroobants S, Dupont P et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278.
3. Naumann R, Vaic A, Beuthien-Baumann B et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.
4. Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123-130.
5. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.
6. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225-1231.
7. Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-1168.
8. Paolini R, Rampin L, Rodella E et al. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: Preliminary results of a prospective study. Nucl Med Rev Cent East Eur 2007; 10: 87-90.
9. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
10. Ng AK, Bernardo MV, Silver B et al. Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 2005; 61: 175-184.
11. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
12. Yahalom J, Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 (Suppl 1): 79-83.
13. Advani R, Maeda L, Lavori P et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007; 25: 3902-3907.
14. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-3994.
15. Picardi M, De Renzo A, Pane F et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007; 48: 1721-1727.
16. Hodgson DC, Koh ES, Tran TH et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007; 110: 2576-2586.
17. Ghalibafian M, Beaudre A, Girinsky T. Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: Dose constraints to virtual volumes or to organs at risk? Radiother Oncol 2008; 87: 82-88.